Cephalexin susceptibility breakpoint for veterinary isolates: Clinical Laboratory Standards Institute revision
- PMID: 29145786
- PMCID: PMC6504153
- DOI: 10.1177/1040638717742434
Cephalexin susceptibility breakpoint for veterinary isolates: Clinical Laboratory Standards Institute revision
Abstract
The Clinical and Laboratory Standards Institute (CLSI) uses cephalothin as the class representative for testing veterinary isolates for susceptibility to other first-generation cephalosporins, including cephalexin. We examined replacing cephalothin with cephalexin because cephalexin is used more often clinically. Bacterial isolates were obtained from dogs and cats from a national surveillance program. CLSI testing methods were used to determine the MIC for 4 cephalosporins used in veterinary medicine. Cephalexin clinical breakpoints for canine isolates were established by using published pharmacokinetic data and Monte Carlo simulations to calculate the probability of target attainment (PTA). For 1,112 Staphylococcus pseudintermedius isolates, the mode, MIC50, and MIC90 were 1, 2, and 64 µg/mL, respectively, for cephalexin, and ≤0.06, 0.12, and 2 µg/mL for cephalothin. Susceptibility of S. pseudintermedius from 2011 to 2014 did not change for the 4 cephalosporins tested. Only 4.3% of the penicillin-binding protein 2a-positive S. pseudintermedius isolates had MIC values ≤2 µg/mL for cephalexin, but 66.3% of these isolates had MIC values ≤2 µg/mL for cephalothin. There were also discrepancies between cephalexin and cephalothin for other bacteria tested, but the largest difference was for S. pseudintermedius, with a MIC difference of 4 doubling dilutions. Cephalexin interpretive categories (breakpoints) of ≤2 μg/mL (susceptible), 4 μg/mL (intermediate), and ≥8 μg/mL (resistant) were established for isolates obtained from dogs. Cephalothin should not be used for susceptibility testing of cephalexin for veterinary bacterial pathogens, and canine-specific breakpoints should be used for testing susceptibility. Breakpoints determined using the methods described herein for the interpretive categories will be added to future CLSI tables to reflect this recommendation.
Keywords: Breakpoints; CLSI; Staphylococcus pseudintermedius; cephalexin; cephalothin; susceptibility testing.
Conflict of interest statement
Figures

Similar articles
-
In vitro comparison of Staphylococcus pseudintermedius susceptibility to common cephalosporins used in dogs.Vet Ther. 2010 Fall;11(3):E1-9. Vet Ther. 2010. PMID: 20960413
-
Pharmacodynamics of doxycycline and tetracycline against Staphylococcus pseudintermedius: proposal of canine-specific breakpoints for doxycycline.J Clin Microbiol. 2013 Nov;51(11):3547-54. doi: 10.1128/JCM.01498-13. Epub 2013 Aug 21. J Clin Microbiol. 2013. PMID: 23966509 Free PMC article.
-
Evaluation of Oxacillin and Cefoxitin Disk and MIC Breakpoints for Prediction of Methicillin Resistance in Human and Veterinary Isolates of Staphylococcus intermedius Group.J Clin Microbiol. 2016 Mar;54(3):535-42. doi: 10.1128/JCM.02864-15. Epub 2015 Nov 25. J Clin Microbiol. 2016. PMID: 26607988 Free PMC article.
-
The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus.Clin Infect Dis. 2007 May 1;44(9):1208-15. doi: 10.1086/513203. Epub 2007 Mar 28. Clin Infect Dis. 2007. PMID: 17407040 Review.
-
Candida and candidaemia. Susceptibility and epidemiology.Dan Med J. 2013 Nov;60(11):B4698. Dan Med J. 2013. PMID: 24192246 Review.
Cited by
-
Comparative effects of systemic administration of levofloxacin and cephalexin on fracture healing in rats.J Korean Assoc Oral Maxillofac Surg. 2022 Apr 30;48(2):94-100. doi: 10.5125/jkaoms.2022.48.2.94. J Korean Assoc Oral Maxillofac Surg. 2022. PMID: 35491140 Free PMC article.
-
Molecular Detection and Characterization of the mecA and nuc Genes From Staphylococcus Species (S. aureus, S. pseudintermedius, and S. schleiferi) Isolated From Dogs Suffering Superficial Pyoderma and Their Antimicrobial Resistance Profiles.Front Vet Sci. 2020 Jul 23;7:376. doi: 10.3389/fvets.2020.00376. eCollection 2020. Front Vet Sci. 2020. PMID: 32793641 Free PMC article.
-
Evidence for Establishing the Clinical Breakpoint of Cefquinome against Haemophilus Parasuis in China.Pathogens. 2021 Jan 22;10(2):105. doi: 10.3390/pathogens10020105. Pathogens. 2021. PMID: 33498972 Free PMC article.
References
-
- Angarano DW, MacDonald JM. Efficacy of cefadroxil in the treatment of bacterial dermatitis in dogs. J Am Vet Med Assoc 1989;194:57–59. - PubMed
-
- Barry AL, et al. Reassessment of the “class” concept of disk susceptibility testing: cephalothin disks versus minimal inhibitory concentrations with eleven cephalosporins. Am J Clin Pathol 1978;70:909–913. - PubMed
-
- Campbell BG, Rosin E. Effect of food on absorption of cefadroxl and cephalexin in dogs. J Vet Pharmacol Ther 1998;21:418–420. - PubMed
-
- Carli S, et al. Absorption kinetics and bioavailability of cephalexin in the dog after oral and intramuscular administration. J Vet Pharmacol Ther 1999;22:308–313. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous